The sponsors of two cancer drugs that lost their fast-track status while under review at the European Medicines Agency should learn this week whether the new treatments will be recommended for pan-EU approval.
One of the products is selinexor, Karyopharm Therapeutics’ orphan drug for treating relapsed or refractory multiple myeloma. The other is dostarlimab – GlaxoSmithKline’s endometrial cancer treatment. It is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?